Stephan A. Grupp

This study develops a method to generate optimized peptide ligands for CAR-T cell restimulation, demonstrating enhanced expansion and memory development in preclinical models.

This study identifies IKAROS as a factor associated with antigen escape in B-ALL, showing that low IKAROS levels lead to reduced B-cell antigen expression and resistance to CD19- and CD22-targeted therapies.

This study shows that targeting TET2 in CAR T-cells improves their anti-tumor responses by limiting terminal exhaustion and enhancing therapeutic potential.

This study identifies impaired death receptor signaling as a driver of resistance to CAR T cell therapy in B-cell leukemia by showing its role in tumor survival and T cell dysfunction.